Singapore markets closed

Straits Times Index
3,290.70
+24.75(+0.76%)
Nikkei
38,229.11
+155.13(+0.41%)
Hang Seng
18,963.68
+425.87(+2.30%)
FTSE 100
8,433.76
+52.41(+0.63%)
Bitcoin USD
60,832.29
-1,796.41(-2.87%)
CMC Crypto 200
1,302.78
-55.23(-4.21%)

Merck & Co., Inc. (MRK)

NYSE - Nasdaq Real-time price. Currency in USD

Add to watchlist

130.06

-0.17

(-0.13%)

At close: 04:00PM EDT

129.95

-0.11

(-0.08%)

After hours:

06:06PM EDT

Trade prices are not sourced from all markets

Press releases

CNW Group
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with gemcitabine-based chemotherapy, for the treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma (BTC). This approval is based on the results from the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant and clinically meaningful improvem
Business Wire
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
RAHWAY, N.J., May 09, 2024--Merck Provides Update on Phase 3 KEYNOTE-B21 Trial
Business Wire
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
RAHWAY, N.J., May 08, 2024--Merck to Participate in the Bank of America Securities 2024 Healthcare Conference